Axsome Therapeutics, INC. (AXSM) — 10-Q Filings

10-Q Filings (6)

• Axsome's Revenue Soars 66% on New Drug Launch, Losses Narrow — Nov 3, 2025 Risk: medium
  Axsome Therapeutics, Inc. (AXSM) reported a significant increase in total revenues for the nine months ended September 30, 2025, reaching $442.497 million, up f
• Axsome's Revenue Soars 75% on Auvelity, Sunosi Sales; Net Loss Narrows — Aug 4, 2025 Risk: medium
  Axsome Therapeutics, Inc. reported a significant increase in product revenue for the three months ended June 30, 2025, reaching $105.2 million, up from $60.1 mi
• Axsome Therapeutics Files Q1 2025 10-Q — May 5, 2025 Risk: medium
  Axsome Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's financial statements reflect its ongoing operations and financial p
• Axsome Therapeutics Q3 2024 Update — Nov 12, 2024 Risk: medium
  Axsome Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operations, in
• Axsome Therapeutics Files Q2 2024 10-Q — Aug 5, 2024 Risk: medium
  Axsome Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance, including details on employee s
• Axsome Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk: medium
  Axsome Therapeutics, Inc. (AXSM) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Axsome Therapeutics, Inc. filed a 10-Q report for the period endin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX